Citigroup’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-9,763
| Closed | -$233K | – | 6612 |
|
|
2021
Q1 | $233K | Sell |
9,763
-5,928
| -38% | -$110K | ﹤0.01% | 3939 |
|
|
2020
Q4 | $229K | Buy |
15,691
+9,790
| +166% | +$130K | ﹤0.01% | 4884 |
|
|
2020
Q3 | $84K | Sell |
5,901
-17,462
| -75% | -$267K | ﹤0.01% | 5251 |
|
|
2020
Q2 | $344K | Buy |
23,363
+7,236
| +45% | +$73.5K | ﹤0.01% | 4588 |
|
|
2020
Q1 | $66K | Buy |
16,127
+2,819
| +21% | +$13.2K | ﹤0.01% | 5718 |
|
|
2019
Q4 | $64K | Buy |
13,308
+6,094
| +84% | +$33.6K | ﹤0.01% | 6125 |
|
|
2019
Q3 | $44K | Sell |
7,214
-7,989
| -53% | -$49.9K | ﹤0.01% | 6205 |
|
|
2019
Q2 | $99K | Buy |
15,203
+1,208
| +9% | +$8.51K | ﹤0.01% | 5887 |
|
|
2019
Q1 | $99K | Buy |
13,995
+199
| +1% | +$1.31K | ﹤0.01% | 5752 |
|
|
2018
Q4 | $67K | Sell |
13,796
-502
| -4% | -$2.61K | ﹤0.01% | 5997 |
|
|
2018
Q3 | $105K | Buy |
14,298
+6,850
| +92% | +$50.3K | ﹤0.01% | 5863 |
|
|
2018
Q2 | $48K | Buy |
7,448
+7,186
| +2,743% | +$47.5K | ﹤0.01% | 6330 |
|
|
2018
Q1 | $1K | Sell |
262
-172
| -40% | -$855 | ﹤0.01% | 7489 |
|
|
2017
Q4 | $2K | Buy |
434
+275
| +173% | +$1.66K | ﹤0.01% | 7425 |
|
|
2017
Q3 | $2K | Buy |
159
+48
| +43% | +$499 | ﹤0.01% | 7067 |
|
|
2017
Q2 | $1K | Sell |
111
-5
| -4% | -$64 | ﹤0.01% | 7259 |
|
|
2017
Q1 | $1K | Sell |
116
-36,810
| -100% | -$443K | ﹤0.01% | 7134 |
|
|
2016
Q4 | $452K | Buy |
36,926
+33,364
| +937% | +$396K | ﹤0.01% | 4476 |
|
|
2016
Q3 | $42K | Buy |
3,562
+2,079
| +140% | +$20.1K | ﹤0.01% | 5792 |
|
|
2016
Q2 | $13K | Sell |
1,483
-33,277
| -96% | -$228K | ﹤0.01% | 6430 |
|
|
2016
Q1 | $184K | Buy |
34,760
+33,480
| +2,616% | +$186K | ﹤0.01% | 5171 |
|
|
2015
Q4 | $10K | Sell |
1,280
-586
| -31% | -$4.5K | ﹤0.01% | 6831 |
|
|
2015
Q3 | $15K | Sell |
1,866
-912
| -33% | -$8.44K | ﹤0.01% | 6223 |
|
|
2015
Q2 | $25K | Sell |
2,778
-654
| -19% | -$6.6K | ﹤0.01% | 5983 |
|
|
2015
Q1 | $44K | Sell |
3,432
-4,402
| -56% | -$57.6K | ﹤0.01% | 5611 |
|
|
2014
Q4 | $106K | Buy |
7,834
+4,288
| +121% | +$47.9K | ﹤0.01% | 5197 |
|
|
2014
Q3 | $32K | Buy |
3,546
+1,473
| +71% | +$15.8K | ﹤0.01% | 5603 |
|
|
2014
Q2 | $28K | Sell |
2,073
-6,115
| -75% | -$63.8K | ﹤0.01% | 5614 |
|
|
2014
Q1 | $81K | Sell |
8,188
-18,992
| -70% | -$236K | ﹤0.01% | 5168 |
|
|
2013
Q4 | $362K | Buy |
27,180
+27,123
| +47,584% | +$329K | ﹤0.01% | 4105 |
|
|
2013
Q3 | $1K | Buy |
57
+22
| +63% | +$236 | ﹤0.01% | 6716 |
|
|
2013
Q2 | $0 | Buy |
+35
| New | +$483 | ﹤0.01% | 6822 |
|
Citigroup's GNMK Position: Q2 2021 in Review
Citigroup sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 9,763 shares — an estimated $233K sold.
Citigroup first reported a position in GNMK in Q2 2013 and held it in 32 quarters. The position peaked at $452K in Q4 2016. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Citigroup reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Citigroup sold 9,763 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $233K.
- Citigroup first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 32 quarters.
- Citigroup's GenMark Diagnostics, Inc position peaked at $452K in Q4 2016.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Citigroup's 13F filing for Q2 2021, filed 10 Aug 2021.